CSL is one of Australia's largest companies and a global leader in blood plasma products, with its CSL Behring arm making therapies from plasma — including immunoglobulins — alongside the Seqirus influenza-vaccine Business and other operations. A long-standing market darling, CSL (ASX:CSL) had lately fallen out of favour, so its FY26 result and recovery outlook drew intense attention.

Latest Development

For FY26, CSL reported total Revenue of US$15.8 billion, down 1% at constant currency, with underlying net profit after tax and Amortisation of US$3.1 billion, down 2%. However, US$7.1 billion of pre-tax impairments and US$799 million of restructuring costs drove a statutory net loss after tax of US$2.6 billion, which CSL characterised as a reset year. CSL Behring revenue was US$11.4 billion, with immunoglobulin sales broadly flat at about US$6.25 billion and second-half immunoglobulin growth of 7%.

The company announced a new US$1.1 billion buyback and a full-year Dividend of US$2.92, and guided to FY27 underlying net profit growth of approximately 5%, with CSL Behring expected to grow mid-single digits — an outlook the market received well despite the statutory loss.

What Could Drive the Shares Next?

Catalysts include delivery of the FY27 underlying profit-growth guidance, continued recovery in immunoglobulin demand, the outcome of restructuring and any decisions on the Seqirus Vaccine business, and the benefit of the buyback. Evidence that the core plasma business is reaccelerating would be significant.

A demonstrable return to underlying growth would be the clearest positive driver after a reset year.

Risks Investors Should Watch

The scale of the FY26 impairments highlights challenges across parts of the portfolio, and further write-downs cannot be ruled out. Generic and biosimilar competition, regulatory developments, and the performance of the vaccine business are risks.

Plasma collection costs and volumes, and execution on the restructuring, are additional considerations for a company of CSL's scale.

Investor Takeaway

CSL reported a US$2.6 billion statutory loss in FY26 driven by US$7.1 billion of impairments, but Underlying Profit held up and it guided to about 5% underlying growth in FY27 with a new buyback. Whether it surprises depends on the core plasma business reaccelerating and the reset delivering. Immunoglobulin growth, FY27 delivery and restructuring are the things to watch.